Literature DB >> 7678237

Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies.

J Loeper1, V Descatoire, M Maurice, P Beaune, J Belghiti, D Houssin, F Ballet, G Feldmann, F P Guengerich, D Pessayre.   

Abstract

BACKGROUND: Anti-cytochrome P-450 autoantibodies are present in several forms of autoimmune hepatitis. The possibility that cytochromes P-450 are present in the plasma membrane of human hepatocytes was examined.
METHODS: (1) Plasma membranes with microsomal contamination < 1%, as judged from the activities of glucose-6-phosphatase and NADH-cytochrome c reductase, were prepared. (2) After exposure of uncut, fixed hepatocytes to antibodies, immunofluorescence and immunoperoxidase studies were performed.
RESULTS: (1) The specific content of cytochrome P-450 in plasma membrane was 9% of that in microsomes. Plasma membranes showed NADPH-cytochrome c reductase and mono-oxygenase activities; immunoblots showed the presence of cytochromes P-450 1A2, 2C, 2D6, 2E1, and 3A4; cytochromes P-450 1A2, 2D6, and 2C were also recognized by anti-liver microsome and anti-liver/kidney microsome type 1 and type 2 autoantibodies, respectively. (2) Immunofluorescence and immunoperoxidase labeling of the plasma membrane was observed with the three auto-antibodies and with anti-cytochrome P-450 1A2, 2C, 2E1, or 3A4.
CONCLUSIONS: It is concluded that cytochromes P-450 are present and functional in the plasma membrane of human hepatocytes and that anti-cytochrome P-450 autoantibodies recognize epitopes expressed on the outer surface.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678237     DOI: 10.1016/0016-5085(93)90853-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6.

Authors:  D Vergani; G Mieli-Vergani
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

Review 3.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

4.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

5.  Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis.

Authors:  J F Schlaak; H Löhr; H Gallati; K H Meyer zum Büschenfelde; B Fleischer
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

6.  Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.

Authors:  M A Robin; M Maratrat; M Le Roy; F P Le Breton; E Bonierbale; P Dansette; F Ballet; D Mansuy; D Pessayre
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

7.  Pheromone anosmia in a scarab beetle induced by in vivo inhibition of a pheromone-degrading enzyme.

Authors:  Martine Maïbèche-Coisne; Alexander A Nikonov; Yuko Ishida; Emmanuelle Jacquin-Joly; Walter S Leal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

Review 8.  CYP2E1 and oxidative liver injury by alcohol.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  Free Radic Biol Med       Date:  2007-11-17       Impact factor: 7.376

9.  Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Authors:  Fernando Alvarez
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

Review 10.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.